Loading...
Market
Will 23andMe complete restructuring by June 30, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
23andMe's official press releases or financial reports
Story
23andMe Cuts 40% of Workforce, Ends Drug Development
Nov 12, 2024, 12:08 AM
23andMe, a genetic testing firm, has announced a significant restructuring program that includes reducing its workforce by approximately 40%, affecting over 200 employees, and discontinuing its drug development efforts. The company aims to streamline operations, reduce costs, and focus on its consumer genetics business. This restructuring will incur one-time costs of up to $12 million.
View original story
Similar markets
Successful privatization • 25%
Abandoned privatization plan • 25%
Privatization plan still in progress • 25%
Other outcome • 25%
Successfully privatized • 25%
Plan abandoned • 25%
Plan delayed • 25%
Other • 25%
Successful privatization • 25%
Abandoned privatization • 25%
New buyout offer • 25%
Other outcome • 25%
Significantly improved • 25%
Slightly improved • 25%
Unchanged • 25%
Declined • 25%